1/15/2024 0 Comments Xofigo prostate cancershould only be used after two previous treatments or when other treatments cannot be takenĮMA’s safety committee PRAC has recommended restricting the use of the cancer medicine Xofigo (radium-223 dichloride) to patients who have had two previous treatments for metastatic prostate cancer (prostate cancer that has spread to the bone) or who cannot receive other treatments.Rethinking Xofigo: drug's benefits go beyond pain palliation in prostate cancer Alpha emitter radium-223 and survival in metastatic prostate cancer. Parker, C., Nilsson, S., Heinrich, D., Helle, S.Preventing and treating prostate cancer spread to the bones You can learn more about how we ensure our content is accurate and current by reading our editorial policy. We link primary sources - including studies, scientific references, and statistics - within each article and also list them in the resources section at the bottom of our articles. Medical News Today has strict sourcing guidelines and draws only from peer-reviewed studies, academic research institutions, and medical journals and associations. data have shown that Xofigo can be given safely before or after chemotherapy.” This is because it’s an alpha emitter and it actually improves overall survival. “I think the biggest challenge is that oncologists still see it as a palliative tool It is still being put in that same type of class when it really it doesn’t belong there. Oncologists fail to take into account that, because it is an alpha emitter, Xofigo belongs to a different class of treatments: Koo of the University of Colorado Hospital in Aurora, explained that oncologists tend to think of radiopharmaceutical drugs as palliative treatments – drugs to make people feel more comfortable but not necessarily treat the disease. Speaking recently to the oncology website Cure, cancer researcher Phillip J. Xofigo was also found to improve quality of life for these patients and extend the period of time before their first skeletal problem.ĭespite the life-extending properties of Xofigo, some experts have expressed frustration that oncologists largely regard Xofigo as simply a pain-relieving drug for prostate cancer patients. In a 2013 study, patients with metastatic castration-resistant prostate cancer taking Xofigo lived about 3.5 months longer, on average, than those who were given a placebo. Xofigo ‘extends life’ for patients with castration-resistant prostate cancer If the cancer has reached the bones but not spread to other organs, Xofigo can extend the time before skeletal events occur. Skeletal events are the main cause of ill health and death in men with castration-resistant prostate cancer. When cancer reaches the bone, the patient is much more vulnerable to skeletal events these can include pain in the bones and fractures that occur during even quite gentle movements. Metastatic prostate cancer moves into the bones in most patients. These cases are referred to as castration-resistant. However, some forms do not respond to a reduction in this hormone. For this reason, treatment to lower testosterone can help slow the disease’s progression. Testosterone, the male sex hormone, stimulates the growth and spread of prostate cancer. Prostate cancer is a cancer of the prostate, a gland in the male reproductive system located below the bladder and in front of the rectum.Īccording to the American Cancer Center, an estimated 180,890 new cases of prostate cancer will be diagnosed in 2016 and 26,120 men will die from the disease. Share on Pinterest Xofigo helps extend life for prostate cancer patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |